Literature DB >> 14511764

Current topics: brain penetrating neurotensin analog.

Mona Boules1, Paul Fredrickson, Elliott Richelson.   

Abstract

Neurotensin (NT) is a neuropeptide found in the central nervous system and gastrointestinal tract. It is closely associated with dopaminergic and other neurotransmitter systems, and evidence supports a role for NT in various neuropsychiatric disorders. Because NT is readily degraded by peptidases, our group has developed various NT agonists that can be injected systemically, cross the blood brain barrier (BBB), yet retain the characteristics of native NT. The most widely studied and successful of these compounds, called NT69L, holds promise as a therapeutic agent for Parkinson's disease, schizophrenia, psychostimulant abuse and nicotine dependence, and serves as a tool to study the cellular and molecular effects of NT.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14511764     DOI： 10.1016/s0024-3205(03)00674-x

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  8 in total

Review 1.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

2.  Systemically and topically active antinociceptive neurotensin compounds.

Authors:  Grace C Rossi; Joshua E Matulonis; Elliott Richelson; Denise Barbut; Gavril W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  2010-06-24       Impact factor: 4.030

3.  The role of NTS2 in the development of tolerance to NT69L in mouse models for hypothermia and thermal analgesia.

Authors:  Kristin E Smith; Mona Boules; Katrina Williams; Abdul H Fauq; Elliott Richelson
Journal:  Behav Brain Res       Date:  2011-06-21       Impact factor: 3.332

4.  Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia.

Authors:  Zhimin Li; Mona Boules; Katrina Williams; Andres Gordillo; Shuhua Li; Elliott Richelson
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

5.  NT79: A novel neurotensin analog with selective behavioral effects.

Authors:  Mona Boules; Yanqi Liang; Siobhan Briody; Tomofumi Miura; Irfan Fauq; Alfredo Oliveros; Mina Wilson; Shaheen Khaniyev; Katrina Williams; Zhimin Li; Yanfei Qi; Michael Katovich; Elliott Richelson
Journal:  Brain Res       Date:  2009-10-27       Impact factor: 3.252

6.  Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance.

Authors:  Siobhan Briody; Mona Boules; Alfredo Oliveros; Irfan Fauq; Elliott Richelson
Journal:  Behav Brain Res       Date:  2009-10-02       Impact factor: 3.332

Review 7.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

8.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.